March 29, 2021
Takeda Pharmaceutical said on March 25 that the European Medicines Agency (EMA) has accepted its regulatory submission for its tetravalent dengue vaccine candidate TAK-003 for the prevention of the disease. TAK-003 is being developed against all four dengue serotypes in...read more